Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma.

Antibodies (Basel, Switzerland)·2025
Same author

Therapeutics and Clinical Risk Management - 20<sup>th</sup> Anniversary.

Therapeutics and clinical risk management·2025
Same author

Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment.

Advances in pharmacology (San Diego, Calif.)·2023
Same author

Molecular Biology of Eosinophils: Introduction.

Methods in molecular biology (Clifton, N.J.)·2021
Same author

Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.

Expert opinion on biological therapy·2020
Same author

Dupilumab utility in difficult-to-treat asthma.

Immunotherapy·2019

Related Experiment Video

Updated: Jun 27, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Emerging drugs for asthma.

Garry M Walsh1

  • 1Division of Applied Medicine Institute of Medical Sciences, University of Aberdeen Foresterhill, Aberdeen AB25 2ZD, UK.

Expert Opinion on Emerging Drugs
|December 3, 2008
PubMed
Summary
This summary is machine-generated.

New biopharmaceutical therapies are being developed to target airway inflammation in asthma, addressing unmet needs beyond current inhaled corticosteroid treatments. These novel approaches, including monoclonal antibodies, aim to provide disease-modifying treatments for persistent symptomatic asthma.

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Related Experiment Videos

Last Updated: Jun 27, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Area of Science:

  • Pulmonology and immunology
  • Pharmacology and drug development

Background:

  • Current asthma therapies, primarily inhaled corticosteroids, manage symptoms but require lifelong use.
  • A subset of asthma patients remains symptomatic despite optimal treatment, highlighting an unmet medical need.
  • Airway inflammation is recognized as a key factor in asthma pathogenesis.

Purpose of the Study:

  • To review novel biopharmaceutical approaches for asthma therapy.
  • To identify treatments targeting key cells and mediators driving airway inflammation.
  • To explore disease-modifying treatments for asthma.

Main Methods:

  • Review of current drug development areas in asthma therapy.
  • Focus on humanized monoclonal antibodies (mAbs) targeting IgE, IL-4, and IL-5.
  • Exploration of small-molecule receptor antagonists and other targeted pathways.

Main Results:

  • Development of humanized mAbs against key cytokines like IgE, IL-4, and IL-5.
  • Targeting of asthma-relevant cytokines and chemokines via receptor blocking mAbs or soluble receptor constructs.
  • Utilization of small-molecule antagonists and pathways controlling leukocyte accumulation.

Conclusions:

  • Novel biopharmaceutical strategies offer potential disease-modifying treatments for asthma.
  • Monoclonal antibodies and small-molecule antagonists represent significant advancements.
  • Further evaluation of therapeutic potential and challenges of these novel drugs is warranted.